
    
      An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary Focal
      Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome. The aim of this study is to
      explore the effect of CCX140-B, a selective antagonist of C-C chemokine receptor type 2, on
      proteinuria in subjects with FSGS.
    
  